Skip Navigation



Home » Clinical Trials » Alzheimer's Disease

Clinical Trial Details


Research Study Summary

A clinical trial seeking patients for a research study for the treatment of Alzheimer's Disease

Research Study Title

Phase 2 Study of Trans Cranial Magnetic Stimulation as Additional Therapy Patients With Alzheimer's Disease


The primary objective of this trial is to assess the ability of Transcranial Magnetic Stimulation with H coil to prefrontal cortex , with an addition of cognitive brain training, to improve cognitive performance in patients with Alzheimer's disease which received drug treatment. This study is a single-center, double-blind 4 months duration trial.

To Learn more



Both Male and Female


50 to 85 Years

Overall Status


Lead Sponsor



48 Months

Facility Type



Both Male and Female ages 50 Years to 85 Years

Inclusion Criteria:

  1. Men and women aged 50-85.

  2. Diagnosed with Alzheimer's disease for at least one year (by the DSM-IV criteria).

  3. Scored below 24 on the MMSE.

  4. Received drug therapy for their disease, with each treatment having been administered at an acceptable dosage for at least 5 weeks, with either no effect or only partial response.

  5. Answered in the negative to all questions in the pre-TMS treatment safety questionnaire.

  6. Gave their oral and written consent to participate in the trial.

Exclusion criteria:

  1. An additional neurological or psychiatric disorder.

  2. Severe personality disorder.

  3. Uncontrolled hypertension.

  4. History of epilepsy, seizure, or heat convulsion.

  5. History of epilepsy or seizure in first degree relatives.

  6. History of head injury or stroke.

  7. History of metal implants in the head (except dental fillings).

  8. History of surgery entailing metallic implants or known history of any metallic particles in the eye, implanted cardiac pacemaker, cochlear implants, use of neurostimulators, or any medical pumps.

  9. History of migraines in the last six months.

  10. History of drug or alcohol abuse.

  11. Inadequate communication with examiner.

  12. Participation in another clinical study, either concurrent with this trial or in the 3 months preceding it.

  13. Inability to sign a consent form.

Site Locations (1)

Country State City Zip Facility and Contact
Israel Tel Aviv Merchav Clinics
Veronica Vachapov, Dr.

NCT ID: NCT01179373

Date Last Changed: June 13, 2013

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.